Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and TQB2450 in advanced hepatocellular carcinoma
NCT06031480Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Oct 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib, benmelstobart in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
anlotinibbenmelstobart
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06031480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06031480.